Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
Makino
N
N
Dep. of Bioclimatology & Med. Medical Inst. of Bioregulation, Kyushu University, Beppu, Japan.
Hirayama
H
H
Yonemochi
H
H
Yano
K
K
Abe
N
N
D006332:Cardiomegaly / Q000503:physiopathology*; D002839:Chromans / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000503:physiopathology*; D003971:Diastole / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone